ERBB2 and breast carcinoma: Trastuzumab, a monoclonal antibody against epidermal growth factor receptor 2 (HER2), induces receptor internalization and degradation50 and reduces the growth of breast cancer xenografts with loss of integrin αvβ6 and HER2, existing in the same molecular complex on breast cancer cells51.